Published in Health Business Week, February 27th, 2009
The BROADEN™ (BROdmann Area 25 DEep brain Neuromodulation) study is a controlled, multi-site, blinded, clinical study that is evaluating the safety and effectiveness of DBS therapy in patients with depression for whom currently available treatments are not effective. UT Southwestern is one of three U.S. sites currently participating in this clinical study.
The Libra® DBS system being...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2009-02-27)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.